Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Brno, Czechia
- Fakultni nemocnice u sv. Anny
-
Hořice, Czechia
- Levitovo centrum nasledne pece
-
Olomouc, Czechia
- Vojenska nemocnice Olomouc
-
Vsetín, Czechia
- Vsetinska nemocnice
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient suffered from superficial wound of different etiology
- Wounds in terminal phase of healing
- Wounds without visible sign of infection
- Max. size of the wound: 10 x 20 cm (i.e. two pieces of the product)
- Duration of wound treatment of at least 6 weeks
- Subject willing and able to provide written informed consent
- Ability to communicate well with the investigator in local language, and to understand and comply with the requirements of the study
Exclusion Criteria:
- Sloughy or necrotic wound bed
- Severely contaminated or infected wound
- Age < 18 years
- Pregnant or lactating woman
- Subject in terminal stage of living
- Subject with cancer disease
- Subject with known hypersensitivity or allergy to any component of the investigational device
- Subject participating in other interventional clinical trial
- Alcohol and/or drug abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Patients treated with Epipad
Epipad
|
Device is placed directly onto the treated wound.
The wound should be cleaned with antiseptic solution prior to the device administration.
The device is fixed on the wound by secondary dressing: e.g.
plaster, compression.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the wound dimensions (width x length)
Time Frame: Week 3
|
Change in the wound dimensions from baseline
|
Week 3
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PT-EPI-1_09-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.